NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03080805,Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE),https://clinicaltrials.gov/study/NCT03080805,,UNKNOWN,"Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This study is a randomized,open-label,multi-center,active-controlled, parallel design study of the combination of pyrotinib and capecitabine versus Lapatinib plus capecitabine in HER2+ MBC patients, who have prior received taxane and trastuzumab.Patients will be randomized in a 1:1 ratio to one of the following treatment arms.Arm A: pyrotinib (400 mg once daily) + capecitabine (1000 mg/m\^2 twice daily),Arm B: Lapatinib (1250 mg once daily) + capecitabine (1000 mg/m\^2 twice daily).Patients will receive either arm of therapy until disease progression, unacceptable toxicity, or withdrawalof consent.",NO,HER2 Positive Metastatic Breast Cancer,DRUG: Pyrotinib Plus Capecitabine|DRUG: Lapatinib Plus Capecitabine,"Progression Free Survival(PFS), From infromed consent to progression or death, Estimated 10 months","Safety: AE, AE, AE recorded from infromed consent to 28 days after treatment completion|Overall Survival (OS), From infromed consent to death, Estimated 30 months|Objective Response Rate (ORR), CR+PR, Estimated 10 months|Time to Progression (TTP), From infromed consent to progression, Estimated 10 months|Duration of Response (DOR), CR+PR+SD, Estimated 10 months|Clinical Benefit rate (CBR), CR+PR+SD≥24 weeks, Estimated 10 months",,"Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,240,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,HR-BLTN-Ⅲ-MBC,2017-05-03,2019-03-31,2021-03,2017-03-15,,2020-06-18,"Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China",
